scholarly journals Effects of Serum 25-Hydroxyvitamin D Level on Decreased Bone Mineral Density at Femoral Neck and Total Hip in Chinese Type 2 Diabetes v1 (protocols.io.kjycupw)

protocols.io ◽  
2017 ◽  
Author(s):  
Liting Guo
Keyword(s):  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Femoral Neck ◽  
Bone Mineral ◽  
Mineral Density ◽  
Total Hip ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

scholarly journals Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Ting-ting Cai ◽  
Hui-qin Li ◽  
Lan-lan Jiang ◽  
Hui-ying Wang ◽  
Meng-hui Luo ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Placebo Group ◽  
Femoral Neck ◽  
Insulin Glargine ◽  
Mineral Density ◽  
Total Hip

Introduction. Hypoglycemic drugs affect the bone quality and the risk of fractures in patients with type 2 diabetes mellitus (T2DM). We aimed to investigate the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and insulin on bone mineral density (BMD) in T2DM. Methods. In this single-blinded study, a total of 65 patients with T2DM were randomly assigned into four groups for 52 weeks: the exenatide group ( n = 19 ), dulaglutide group ( n = 19 ), insulin glargine group ( n = 10 ), and placebo ( n = 17 ). General clinical data were collected, and BMD was measured by dual-energy X-ray absorptiometry. Results. Compared with baseline, the glycosylated hemoglobin (HbA1c) decreased significantly in the exenatide ( 8.11 ± 0.24 % vs. 7.40 ± 0.16 % , P = 0.007 ), dulaglutide ( 8.77 ± 0.37 % vs. 7.06 ± 0.28 % , P < 0.001 ), and insulin glargine ( 8.57 ± 0.24 % vs. 7.23 ± 0.25 % , P < 0.001 ) groups after treatment. In the exenatide group, the BMD of the total hip increased. In the dulaglutide group, only the BMD of the femoral neck decreased ( P = 0.027 ), but the magnitude of decrease was less than that in the placebo group; the BMD of L1-L4, femoral neck, and total hip decreased significantly ( P < 0.05 ) in the placebo group, while in the insulin glargine group, the BMD of L2, L4, and L1-4 increased ( P < 0.05 ). Compared with the placebo group, the BMD of the femoral neck and total hip in the exenatide group and the insulin glargine group were increased significantly ( P < 0.05 ); compared with the exenatide group, the BMD of L4 in the insulin glargine group was also increased ( P = 0.001 ). Conclusions. Compared with the placebo, GLP-1RAs demonstrated an increase of BMD at multiple sites of the body after treatment, which may not exacerbate the consequences of bone fragility. Therefore, GLP-1RAs might be considered for patients with T2DM. This trial is registered with ClinicalTrials.gov NCT01648582.

scholarly journals Type 2 diabetes and Change in Total Hip Bone Area and Bone Mineral Density in Elderly Swedish Men and Women

2021 ◽  
Author(s):  
Adam Mitchell ◽  
Tove Fall ◽  
Håkan Melhus ◽  
Lars Lind ◽  
Karl Michaëlsson ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Bone Mineral ◽  
Meta Analysis ◽  
Cross Sectional Study ◽  
Bone Area ◽  
Mineral Density ◽  
Cross Sectional ◽  
Total Hip

Abstract Context In a cross-sectional study, we found an association between type 2 diabetes mellitus (T2DM) and smaller bone area together with a greater bone mineral density (BMD) at the total hip. Objective To investigate these associations longitudinally, by studying T2DM status (no T2DM n=1521, incident T2DM n=119 or prevalent T2DM n=106) in relation to changes in total hip bone area and BMD. Methods In three cohorts, the Swedish Mammography Cohort Clinical (SMCC; n=1060, Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS; n=483) and Uppsala Longitudinal Study of Adult Men (ULSAM; n=203), with repeat assessment of T2DM status and dual energy x-ray absorptiometry (DXA) measurements of total hip bone area and BMD on average 8 years apart, a linear regression model was used to assess the effect of T2DM status on change in bone area and BMD at the total hip. Results After meta-analysis, the change in bone area at the total hip was 0.5% lower among those with incident T2DM compared to those without T2DM (-0.18 cm 2 [95% CI -0.30, -0.06]). The change in bone area was similar among those with prevalent T2DM compared to those without (0.00 cm 2 [95% CI -0.13, 0.13]). For BMD, the combined estimate was 0.004 g/cm 2 (95% CI -0.006, 0.014) among those with incident T2DM and 0.010 g/cm 2 (95% CI -0.000, 0.020) among those with prevalent T2DM, compared to those without T2DM. Conclusion Those with incident T2DM have a lower expansion in bone area at the total hip compared to those without T2DM.

Bone mineral density in male patients with type 2 diabetes mellitus, with and without hypogonadism

2017 ◽  
Author(s):  
Agathi Vasileiou ◽  
Ioanna Karathanassi ◽  
Parthena Navrozidou ◽  
Marianna Vlychou ◽  
Georgios Koukoulis ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Bone Mineral ◽  
Mineral Density ◽  
Male Patients

Predictors and relationships of serum 25 hydroxyvitamin D concentration with bone turnover markers, bone mineral density, and vitamin D receptor genotype in Emirati women

Bone ◽  
2006 ◽  
Vol 39 (5) ◽  
pp. 1136-1143 ◽  
Author(s):  
Hussein F. Saadi ◽  
Nicolaas Nagelkerke ◽  
Sheela Benedict ◽  
Hussein S. Qazaq ◽  
Erica Zilahi ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vitamin D ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Vitamin D Receptor ◽  
Bone Turnover Markers ◽  
Mineral Density ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Turnover Markers
Sign in / Sign up

Export Citation Format

Share Document